We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Study Finds Excessive Testing Prescribed for Monoclonal Gammopathy Patients

By LabMedica International staff writers
Posted on 17 May 2016
A retrospective analysis has determined that the tests for M-protein that physicians routinely order to help diagnose and monitor patients with the age-related immune disorder monoclonal gammopathy (MG), often do not benefit the patient. Pathologists who performed the study have proposed an optimizing algorithm for more effective decision-making based on the evidence for clinical value.

Instead of ordering individual tests, physicians request an initial workup for MG, said study leader Dr. Gurmukh Singh, chief of Clinical Pathology, Medical College of Georgia, Augusta University (Augusta, GA, USA). Once pathologists examine a patient’s medical record and interpret results of a screening test for M-protein using serum protein electrophoresis (SPEP) – they can use the new algorithm to decide in a stepwise fashion what, if any, additional tests are warranted.

The cause of monoclonal gammopathy is unclear, but the risk tends to increase with age. Usually not detectable from routine lab tests, some physicians specifically screen for the condition in patients over age 50.

A review of experience at a medium-sized teaching hospital in Georgia, as well an earlier study in Missouri, found that ~50% of the time physicians order tests that ultimately don’t benefit their patients. The study reviewed the history of 237 patients age 19-87 who had a total of 1,503 episodes of testing. In addition to SPEP, many patients also had the more expensive serum immunofixation electrophoresis (SIFEP) and/or serum-free light-chain (SFLC) assays for M-Protein. A patient’s physician may order this series of tests dozens of times over several months.

From the examined data, only 46% of SIFEPs and 42% of SFLC assays were warranted. The two tests were ordered multiple times in patients in whom M-Protein was easily detected with SPEP. Indeed, for most patients with measurable levels of M-protein, SPEP can be used alone to monitor course of disease and treatment. Similar test-use patterns are also at play in hospitals across the country.

“About 40-50% of the second tests are not needed or adding value,” said Dr. Singh. The team proposed an algorithm that would put more of the decision-making in the hands of pathologists interpreting the tests. “These are stepwise things. If it’s a new patient, do this; if it’s a known patient, do that. Results drive it. That will reduce the number of tests that are done without in any way being of detriment to the patient or the quality of care,” he added.

A protocol similar to that proposed in the new study has safely enabled up to 60% reduction, over ~8 years, in volume of the additional tests at the Missouri hospital.

Testing should be algorithmically driven based on evidence. Electronic medical records enable these more rigorous approaches by pathologists. Similar approaches could be used for numerous other diseases (e.g. celiac disease) where a battery of tests also is routinely ordered and a stepwise approach might be more prudent.

The study, by Heaton C et al, was published online April 22, 2016, in the American Journal of Clinical Pathology.

Related Links:
Augusta University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.